{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T18:22:39Z","timestamp":1792866159345,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,24]],"date-time":"2018-09-24T00:00:00Z","timestamp":1537747200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Bristol-Myers Squibb"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-4829-0","type":"journal-article","created":{"date-parts":[[2018,9,24]],"date-time":"2018-09-24T12:19:28Z","timestamp":1537791568000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":81,"title":["Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma"],"prefix":"10.1186","volume":"18","author":[{"given":"Emily Z.","family":"Keung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander J.","family":"Lazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keila E.","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Lien","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice N.","family":"Cormier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Ashleigh Guadagnolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly K.","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Bird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerae O.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreyaskumar R.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Wargo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeta","family":"Somaiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina L.","family":"Roland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,24]]},"reference":[{"issue":"3","key":"4829_CR1","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1097\/SLA.0000000000000869","volume":"260","author":"MF Brennan","year":"2014","unstructured":"Brennan MF, Antonescu CR, Moraco N, Singer S. Lessons learned from the study of 10,000 patients with soft tissue sarcoma. Ann Surg. 2014;260(3):416\u201321.","journal-title":"Ann Surg"},{"issue":"2","key":"4829_CR2","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3322\/canjclin.54.2.94","volume":"54","author":"JN Cormier","year":"2004","unstructured":"Cormier JN, Pollock RE. Soft tissue sarcomas. CA Cancer J Clin. 2004;54(2):94\u2013109.","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"4829_CR3","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1245\/s10434-010-0997-0","volume":"17","author":"C-YC-L Liu","year":"2010","unstructured":"Liu C-YC-L, Yen C, Chen W-M, et al. Soft tissue sarcoma of extremities: the prognostic significance of adequate surgical margins in primary operation and reoperation after recurrence. Ann Surg Oncol. 2010;17(8):2102\u201311.","journal-title":"Ann Surg Oncol"},{"key":"4829_CR4","unstructured":"National Cancer Institute. A snapshot of sarcoma. Accessed 9 July 2018. \n                    https:\/\/www.cancer.gov\/types\/soft-tissue-sarcoma\/hp\/adult-soft-tissue-treatment-pdq\n                    \n                  ."},{"issue":"4","key":"4829_CR5","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/S0360-3016(00)00753-7","volume":"48","author":"KM Alektiar","year":"2000","unstructured":"Alektiar KM, Velasco J, Zelefsky MJ, Woodruff JM, Lewis JJ, Brennan MF. Adjuvant radiotherapy for margin-positive high-grade soft tissue sarcoma of the extremity. Int J Radiat Oncol Biol Phys. 2000;48(4):1051\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"4829_CR6","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/j.ijrobp.2006.11.035","volume":"67","author":"TF Delaney","year":"2007","unstructured":"Delaney TF, Kepka L, Goldberg SI, et al. Radiation therapy for control of soft-tissue sarcomas resected with positive margins. Int J Radiat Oncol Biol Phys. 2007;67(5):1460\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"4829_CR7","doi-asserted-by":"publisher","first-page":"373","DOI":"10.20892\/j.issn.2095-3941.2016.0028","volume":"13","author":"SS Tiong","year":"2016","unstructured":"Tiong SS, Dickie C, Haas RL, O\u2019Sullivan B. The role of radiotherapy in the management of localized soft tissue sarcomas. Cancer Biol Med. 2016;13(3):373\u201383.","journal-title":"Cancer Biol Med"},{"issue":"4","key":"4829_CR8","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.soc.2016.05.012","volume":"25","author":"NA Larrier","year":"2016","unstructured":"Larrier NA, Czito BG, Kirsch DG. Radiation therapy for soft tissue sarcoma: Indications and Controversies for Neoadjuvant Therapy, Adjuvant Therapy, Intraoperative Radiation Therapy, and Brachytherapy. Surg Oncol Clin N Am. 2016;25(4):841\u201360.","journal-title":"Surg Oncol Clin N Am"},{"issue":"9325","key":"4829_CR9","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1016\/S0140-6736(02)09292-9","volume":"359","author":"B O\u2019Sullivan","year":"2002","unstructured":"O\u2019Sullivan B, Davis AM, Turcotte R, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet. 2002;359(9325):2235\u201341.","journal-title":"Lancet"},{"issue":"6","key":"4829_CR10","first-page":"604","volume":"18","author":"R Ratan","year":"2016","unstructured":"Ratan R, Patel SR. Chemotherapy for soft tissue sarcoma. Cancer. 2016;18(6):604\u201310.","journal-title":"Cancer"},{"issue":"6","key":"4829_CR11","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s11864-015-0345-5","volume":"16","author":"M Burgess","year":"2015","unstructured":"Burgess M, Tawbi H. Immunotherapeutic approaches to sarcoma. Curr Treat Options in Oncol. 2015;16(6):26.","journal-title":"Curr Treat Options in Oncol"},{"key":"4829_CR12","doi-asserted-by":"publisher","first-page":"9757219","DOI":"10.1155\/2016\/9757219","volume":"2016","author":"D Mitsis","year":"2016","unstructured":"Mitsis D, Francescutti V, Skitzki J. Current immunotherapies for sarcoma: clinical trials and rationale. Sarcoma. 2016;2016:9757219.","journal-title":"Sarcoma"},{"issue":"21","key":"4829_CR13","doi-asserted-by":"publisher","first-page":"4753","DOI":"10.1158\/1078-0432.CCR-15-0831","volume":"21","author":"J Lim","year":"2015","unstructured":"Lim J, Poulin NM, Nielsen TO. New strategies in sarcoma: linking genomic and immunotherapy approaches to molecular subtype. Clin Cancer Res. 2015;21(21):4753\u20139.","journal-title":"Clin Cancer Res"},{"key":"4829_CR14","first-page":"e558","volume":"35","author":"SPD Angelo","year":"2016","unstructured":"Angelo SPD. Manipulating the immune system with checkpoint inhibitors for patients with metastatic sarcoma. ASCO Educ B. 2016;35:e558\u201364.","journal-title":"ASCO Educ B"},{"issue":"1","key":"4829_CR15","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13569-016-0064-0","volume":"6","author":"L Paoluzzi","year":"2016","unstructured":"Paoluzzi L, Cacavio A, Ghesani M, et al. Response to anti-PD1 therapy with nivolumab in metastatic sarcomas. Clin Sarcoma Res. 2016;6(1):24.","journal-title":"Clin Sarcoma Res"},{"issue":"7457","key":"4829_CR16","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nature12213","volume":"499","author":"MS Lawrence","year":"2013","unstructured":"Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499(7457):214\u20138.","journal-title":"Nature"},{"issue":"2","key":"4829_CR17","doi-asserted-by":"publisher","first-page":"e1385689","DOI":"10.1080\/2162402X.2017.1385689","volume":"7","author":"EZ Keung","year":"2018","unstructured":"Keung EZ, Tsai J-W, Ali AM, et al. Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy. Oncoimmunology. 2018;7(2):e1385689.","journal-title":"Oncoimmunology"},{"issue":"4","key":"4829_CR18","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.cell.2017.10.014","volume":"171","author":"Cancer Genome Atlas Research Network","year":"2017","unstructured":"Cancer Genome Atlas Research Network. Electronic address: elizabeth.demicco@sinaihealthsystem.ca, Cancer genome atlas research network. Comprehensive and integrated genomic characterization of adult soft tissue sarcomas. Cell. 2017;171(4):950\u201365.","journal-title":"Cell"},{"key":"4829_CR19","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","volume":"18","author":"HA Tawbi","year":"2017","unstructured":"Tawbi HA, Burgess M, Bolejack V, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017;18:1493\u2013501.","journal-title":"Lancet Oncol"},{"issue":"7","key":"4829_CR20","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1172\/JCI69219","volume":"123","author":"A Kalbasi","year":"2013","unstructured":"Kalbasi A, June CH, Haas N, Vapiwala N. Radiation and immunotherapy: a synergistic combination. J Clin Invest. 2013;123(7):2756\u201363.","journal-title":"J Clin Invest"},{"issue":"9","key":"4829_CR21","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1158\/2326-6066.CIR-14-0069","volume":"2","author":"C Tang","year":"2014","unstructured":"Tang C, Wang X, Soh H, et al. Combining radiation and immunotherapy: a new systemic therapy for solid tumors? Cancer Immunol Res. 2014;2(9):831\u20138.","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"4829_CR22","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1097\/PPO.0000000000000181","volume":"22","author":"Jonathan E. Schoenhals","year":"2016","unstructured":"Schoenhals JE, Seyedin SN, Tang C, et al. Preclinical Rationale and Clinical Considerations for Radiotherapy Plus Immunotherapy: Going Beyond Local Control. Cancer J. 22(2):130\u20137.","journal-title":"The Cancer Journal"},{"issue":"2","key":"4829_CR23","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.ijrobp.2017.02.087","volume":"98","author":"I-M Schaefer","year":"2017","unstructured":"Schaefer I-M, Hornick JL, Barysauskas CM, et al. Histologic appearance after preoperative radiation therapy for soft tissue sarcoma: assessment of the European Organization for Research and Treatment of Cancer-soft tissue and bone sarcoma group response score. Int J Radiat Oncol Biol Phys. 2017;98(2):375\u201383.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6161","key":"4829_CR24","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1126\/science.1240527","volume":"342","author":"N Iida","year":"2013","unstructured":"Iida N, Dzutsev A, Stewart CA, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science. 2013;342(6161):967\u201370.","journal-title":"Science"},{"issue":"6371","key":"4829_CR25","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","volume":"359","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359(6371):97\u2013103.","journal-title":"Science"},{"key":"4829_CR26","volume-title":"Tumor microbiome mediated-chemoresistance. Paper presented at: Special Conference: EACR-AACR-SIC","author":"R Straussman","year":"2015","unstructured":"Straussman R, Barzily-Rokni M, Cooper ZA, et al. Tumor microbiome mediated-chemoresistance. Paper presented at: Special Conference: EACR-AACR-SIC. Flore: Anticancer Drug Action and Drug Resistance: from Cancer Biology to the Clinic; June 20\u201323, 2015; 2015."},{"key":"4829_CR27","volume-title":"Evidence implicating the commensal microbiota in shaping anti-tumor immunity in melanoma","author":"A Sivan","year":"2014","unstructured":"Sivan A, Corrales L, Gajewski TF. Evidence implicating the commensal microbiota in shaping anti-tumor immunity in melanoma. National Harbor: Paper presented at: 29th annual meeting of the Society for Immunotherapy of Cancer (SITC); 2014; 2014."},{"issue":"6161","key":"4829_CR28","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1126\/science.1240537","volume":"342","author":"S Viaud","year":"2013","unstructured":"Viaud S, Saccheri F, Mignot G, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science. 2013;342(6161):971\u20136.","journal-title":"Science"},{"issue":"379","key":"4829_CR29","doi-asserted-by":"publisher","first-page":"eaah3560","DOI":"10.1126\/scitranslmed.aah3560","volume":"9","author":"Whijae Roh","year":"2017","unstructured":"Roh W, Chen P-L, Reuben A, et al. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med. 2017;9(379). \n                    https:\/\/doi.org\/10.1126\/scitranslmed.aah3560\n                    \n                  .","journal-title":"Science Translational Medicine"},{"issue":"1","key":"4829_CR30","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/biomet\/73.1.13","volume":"73","author":"K Liang","year":"1986","unstructured":"Liang K, Zeger S. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73(1):13\u201322.","journal-title":"Biometrika"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4829-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-018-4829-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4829-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T04:26:56Z","timestamp":1589948816000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-4829-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,24]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["4829"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-4829-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,24]]},"assertion":[{"value":"21 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by The University of Texas MD Anderson Cancer Center Institutional Review Board (IRB; IRB reference number 2017\u20130143) and will be conducted in agreement with the requirements of the Code of Federal Regulations and the Institutional Review Board. All patients will be required to sign an IRB-approved consent form, indicating their agreement to participate. The consent form includes the nature, objectives, and potential risks and benefits of the study and details the required length of follow-up, required tissue biopsies and blood sample collections, supportive care, the name of the principal investigator (CLR) responsible for the protocol. The consent additionally specifies the patient\u2019s right to accept or refuse treatment and to terminate participation and withdraw from the protocol. All data collection with be performed in accordance with the human subjects research policies of MD Anderson Cancer Center.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"913"}}